by stefan | Feb 8, 2021 | Blog
Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center – Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies – Seed investment by Swanbridge Capital and Van Herk Ventures with support from...
by stefan | Nov 24, 2020 | Blog
Ghent, Belgium / Rotterdam, The Netherlands / Miami, FL, USA – November 24, 2020 Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing treatments that dampen hyperactive...
by stefan | Sep 29, 2020 | Blog
Official launch of Immagene: Dutch company developing next-generation immuno-oncology therapeutics Immagene B.V. launched this month as a private biotech company developing next-generation precision immuno-oncology (IO) treatments. The company based in...
by stefan | Oct 30, 2019 | Blog
3 October 2019 Life sciences seed capital fund Curie Capital today announced the closing of a seed investment in Allero Therapeutics, a biopharmaceutical company focused on the development of novel immunotherapies. The company has developed a proprietary platform...
by stefan | Apr 17, 2019 | Blog
ROTTERDAM, 17 April 2019 – Swanbridge Capital, an early-stage Life Sciences venture capital fund, today announced the closing of a Seed investment in Allero Therapeutics, a biopharmaceutical company focused on the discovery and development of novel immunotherapies....
by stefan | Dec 21, 2018 | Blog, Geen categorie
TILBURG, The Netherlands, 20 December 2018 – DegenRx B.V. a biopharmaceutical company developing novel therapeutic solutions to treat neurodegenerative diseases, announced today that they have secured financing for their antibody-based gene therapy program for the...
Recent Comments